E

WIPO-ESCWA/IP/BEY/ 03/4

ORIGINAL: English **DATE:** April 2003







LEBANESEREPUBLIC

UNITEDNATIONSECONOMIC ANDSOCIALCOMMISSIONFOR WESTERNASIA(ESCWA) WORLDINTELLECTUAL PROPERTYORGANIZATION

WIPO-ESCWAARABREGI ONALCONFERENCEONR ECENT DEVELOPMENTSINTHE FIELDOFINTELLECTUA LPROPERTY

organizedby
theWorldIntellectualPropertyOrganization(WIPO)
and
theUnitedNationsEconomicandSocialCommissionforWesternAsia
(ESCWA)

 $incooperation with \\the Ministry of Economy and Trade$

Beirut, May 5 and 6, 2003

INTELLECTUALPROPERTY, BIOTECHNOLOGY AND PUBLICHEALTH

IP and Public Health

patents on pharmaceutical products and access to medicines

Giulio C. Zanetti, IDLO Beirut, May 2003



Why are medicines expensive?

Because they are DIFFICULT, EXPENSIVE, TIME-CONSUMING

to

- > discover
- ➤ develop
- **≻**test
- → obtain Govern. authorization



CONSEQUENCE:

...the inventor is entitled to a reward (monopoly)

necessary to encourage R & D ---- DEVELOPMENT!

!!! Benefit for humanity !!!



«...balance of rights and obligations»

between

А

В

users

i.e. patients

 pharmaceutical comp. (to recup. investments)

humanity

 (to have new drugs)



Is the TRIPS Agreement the real problem?

NO, because

-flexibility clauses in TRIPS

- 2) many countries are not (yet) bound by TRIPS
- 3) Doha Declaration



Are patents the real problem?

NO, because

- -most antiretrovirals are not patented
 - ■no patent law
 - ☐no patents on drugs
 - no application
 - no registration
- 2) Even most basic drugs are not available/ affordable



REAL PROBLEM:

LACK OF FINANCIAL RESOURCES TO CREATE A PROPER HEALTH CARE INFRASTRUCTURE for

- testing
- storing
- distributing
- monitoring
- increasing awareness/knowledge



POST-DOHA DEVELOPMENT AGENDA

status of negotiations

possible solutions



www.wto.org

gzanetti@idlo.int

